[Fazit und Schlussfolgerungen] Das vorliegende Gutachten ergänzt die in den Fachkreisen primär unter arzneimittelrechtlichen Gesichtspunkten geführte Diskussion einer Packungsgrößenbegrenzung rezeptfreier Analgetika um Argumente aus der gesundheitspolitischen und insbesondere der...

We review regulation of two important parameters for third-party payers and manufacturers of prescription drugs: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 original EU member countries (EU-15) and in European Free...

Treatment costs for type 2 diabetes account for a substantial amount of the expenses for statutory health care funds. Within a study sample of the year 2005, 6.8 % of the insured were being treated for type 2 diabetes mellitus. Compared to the non-diabetic insured in the sample, patients...